Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Part 3. Imatinib for Chronic Myeloid Leukemia (CML) (continued)


References

1. Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101(10):3794-800.

2. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine 2002;346(9):645-52.

3. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99(10):3530-9.

4. Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003;88(11):1213-20.

5. Cortes J, Talpaz M, O'Brien S, et al. Clinical significance of molecular monitoring in chronic myeloid leukemia (CML) in chronic phase (CP) with imatinib therapy. Blood 2004;104(11):Abstract #272.

6. Wu CJ, Neuberg D, Chillemi A, et al. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leukemia & Lymphoma 2002;43(12):2281-9.

7. Stentoft J, Pallisgaard N, Kjeldsen E, et al. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. European Journal of Haematology 2001;67(5-6):302-8.

8. Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004;103(6):2284-90.

9. Moravcova J, Zmekova V, Klamova H, et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leukemia Research 2004;28(4):415-9.

10. Paschka P, Muller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003;17(9):1687-94.

11. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine 2003;349(15):1423-32.

12. Kantarjian H, Talpaz M, O'Brien SS, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004;103(8):2873-8.

13. Goldman JM, Melo JV. Chronic myeloid leukemia?Advances in biology and new approaches to treatment. New England Journal of Medicine 2003;349(15):1451-64.

14. Sawyers CL. Chronic myeloid leukemia. New England Journal of Medicine Apr 29 1999;340(17):1330-40.

15. American Cancer Society. Cancer Facts and Figures 2005. 2005; http://www.cancer.org/docroot/STT/stt_0.asp. Accessed March 25, 2005.

16. Faderl S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Annals of Internal Medicine Aug 3 1999;131(3):207-19.

17. Lee SJ, Anasetti C, Horowitz MM, et al. Initial therapy for chronic myelogenous leukemia: playing the odds. Journal of Clinical Oncology Sep 1998;16(9):2897-903.

18. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97(9):2229-35.

19. National Cancer Institute. Chronic Myelogenous Leukemia (PDQ®): Treatment: Health Professional Version; 2005. [Accessed at http://www.cancer.gov/cancertopics/pdq/treatment/CML/healthprofessional/allpages September 23, 2005]

20. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. British Journal of Haematology 1997;96(1):111-6.

21. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New England Journal of Medicine 1988;319(15):990-8.

22. O'Brien S, Tefferi A, Valent P. Chronic myelogenous leukemia and myeloproliferative disease. Hematology (Am Soc Hematol Educ Program) 2004:146-2.

23. Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood Nov 1 1998;92(9):3362-7.

24. Onida F, Ball G, Kantarjian HM, et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer Oct 15 2002;95(8):1673-84.

25. Cortes JE, Talpaz M, Beran M, et al. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer Jan 15 1995;75(2):464-70.

26. Martiat P, Michaux JL, Rodhain J. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood Jul 1 1991;78(1):205-11.

27. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101(12):4701-7.

28. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61(7):1441-6.

29. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood Aug 1 1993;82(3):691-703.

30. Sokal JE, Baccarani M, Russo D, et al. Staging and prognosis in chronic myelogenous leukemia. Seminars in Hematology Jan 1988;25(1):49-61.

31. Savage DG, Szydlo RM, Chase A, et al. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. British Journal of Haematology Oct 1997;99(1):30-5.

32. Branford S, Rudzki Z, Grigg A, et al. BCR-ABL levels continue to decrease up to 42 months after commencement of standard dose imatinib in patients with newly diagnosed chronic phase CML who achieve a major molecular response. Blood 2004;104(11):Abstract #274.

33. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003;17(12):2401-9.

34. van Rhee F, Szydlo RM, Hermans J, et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 1997;20(7):553-60.

35. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17(3):481-7.

36. Barrett AJ, Malkovska V. Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. British Journal of Haematology 1996;93(4):754-61.

37. Cervantes F, Hernandez-Boluda JC, Odriozola J, et al. Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. British Journal of Haematology 2003;120(3):500-4.

38. Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 2003;102(13):4298-305.

39. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood Jul 1 2003;102(1):31-5.

40. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer Feb 15 2003;97(4):1033-41.

41. Anonymous. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. Journal of the National Cancer Institute Nov 5 1997;89(21):1616-20.

42. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. New England Journal of Medicine Jul 24 1997;337(4):223-9.

43. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood Jul 15 1993;82(2):398-407.

44. Kantarjian H, O'Brien S, Cortes J, et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clinical Cancer Research 2004;10(1 Pt 1):68-75.

45. Silver RT. Molecular Biology of CML. In: Bast RC, Kufe D, Pollock RE, et al., eds. Cancer Medicine 5 ed. Hamilton, Ontario: BC Decker; 2000.

46. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute Jun 3 1998;90(11):850-8.

47. Thomas MJ, Irving JA, Lennard AL, et al, On behalf of the Northern Region Haematology Group. Validation of the Hasford score in a demographic study in chronic granulocytic leukaemia. Journal of Clinical Pathology Jun 2001;54(6):491-3.

48. Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. British Journal of Haematology 2003;120(6):990-9.

49. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematologica 2002;107(2):76-94.

50. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood Aug 15 2003;102(4):1160-8.

51. Huntly BJ, Guilhot F, Reid AG, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood Sep 15 2003;102(6):2205-12.

52. Huntly BJ, Bench AJ, Delabesse E, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood Jun 15 2002;99(12):4547-53.

53. Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood Sep 15 2001;98(6):1732-8.

54. Sinclair PB, Nacheva EP, Leversha M, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood Feb 1 2000;95(3):738-43.

55. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16(11):2190-6.

56. U.S. Food and Drug Administration. Gleevac approved for the first line treatment of chronic myeloid leukemia (CML). December 20, 2002; http://www.fda.gov/bbs/topics/NEWS/2002/NEW00860.html. Accessed July 5, 2005.

57. Robinson KA, Dickersin KO. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31(1):150-3.

58. National Institute for Clinical Excellence. Guidance on the use of imatinib for chronic myeloid leukaemia. London: National Institute for Clinical Excellence; 2003.

59. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine 2003;348(11):994-1004.

60. Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. Journal of Clinical Oncology 2003;21(11):2138-46.

61. Hahn EA, Glendenning GA. Quality of life on imatinib. Seminars in Hematology 2003;40(2 Suppl 2):31-6.

62. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS Study. Blood 2004;104(11):Abstract #21.

63. Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101(1):97-100.

64. Cortes J, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate treatment in patients (pts) with previously untreated early chronic phase (CP) chronic myeloid leukemia (CML). Blood 2004;104(11):Abstract #999.

65. Hughes T, Branford S, Reynolds J, et al. Higher-dose imatinib (600 mg/day) with selective intensification in newly diagnosed CML patients in chronic phase; cytogenetic response rates at 12 months are superior to IRIS. Blood 2004;104(11):Abstract #1001.

66. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 2001;344(14):1031-7.

67. Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002;100(2):435-41.

68. Marin D, Marktel S, Szydlo R, et al. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa. Lancet 2003;362:617-9.

69. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003;102(1):83-6.

70. Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical Cancer Research Jul 2002;8(7):2177-87.

71. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101(2):473-5.

72. Kantarjian HM, Cortes JE, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood Oct 1 2004;104(7):1979-88.

73. Le Coutre P, Kreuzer KA, Na IK, et al. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. American Journal of Hematology 2003;73(4):249-55.

74. Marin D, Goldman JM, Olavarria E, Apperley JF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood 2003;102(7):2702-4.

75. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia 2003;17(8):1448-53.

76. Pasquini R, Clementino NC, Zanichelli MA, et al. Observational study for evaluation of quality of life in patients with chronic myeloid leukemia (CML) in use of Gleevec® (Imatinib Mesilate). Blood 2004;104(11):Abstract #2932.

77. Fischer T, Reifenrath C, Hess GR, et al. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral Blood stem cell transplantation (PBSCT). Leukemia 2002;16(7):1220-8.

78. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002;100(5):1590-5.

79. O'Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003;98(5):888-93.

80. Hess G, Bunjes D, Siegert W, et al. Durable molecular remissions in patients with relapsed CML post allogeneic stem cell transplantation upon treatment with imatinib-mesylate (Glivec®, STI-571). Follow-up results of a phase II open-label study. Blood 2004;104(11):Abstract #1004.

81. Corsetti MT, Beltrami G, Carella AM. Imatinib achieves high rates of complete citogenetic remission (CCR) in CML patients relapsed after autografting and IFN-alfa therapy. Blood 2004;104(11):Abstract #4656.

82. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clinical Cancer Research 2002;8(5):935-42.

83. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004;104(11):Abstract #23.

84. Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003;17(9):1707-12.

85. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer Apr 15 2005;103(8):1659-69.

86. Deshmukh CD, Saikia T, Bakshi AV, et al.. Imatinib mesylate in chronic myeloid leukemia (CML): A single institution experience of 174 patients. Journal of Clinical Oncology 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 6710.

87. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99(6):1928-37.

88. Cortes J, Talpaz M, O'Brien S, et al. Survival advantage for patients (pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) treated with imatinib. Blood 2004;104(11):Abstract #1006.

89. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine 2001;344(14):1038-42.

90. Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99(10):3547-53.

91. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-{alpha}2b in early chronic-phase chronic myeloid leukemia. Blood December 15, 2004 2004;104(13):4245-51.

92. Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). British Journal of Haematology 2003;120(5):911-3.

93. Steegmann JL, Moreno G, Alaez C, et al. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. Haematologica 2003;88(7):762-8.

94. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Giraudier SO. Adverse cutaneous reactions to imatinib (ST1571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. Journal of the American Academy of Dermatology 2003;48(2):201-6.

95. Al-Ali HK, Krahl R, Orth M, et al. Persistently increased creatine kinase levels in patients with chronic myeloid leukemia treated with imatinib correlate with major cytogenetic remission. Blood 2004;104(11):Abstract #2933.

96. O'Dwyer ME, Mauro MJ, Blasdel C, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood 2004;103(2):451-5.

97. El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. British Journal of Haematology 2004;125(2):187-95.

98. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003;98(12):2636-42.

99. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica 2003;88(3):260-7.

100. Marin D, Horncastle D, Andreasson C, et al. Prognostic impact of percentage CD34 expression in bone marrow trephines of patients with chronic myeloid leukaemia in chronic phase treated with imatinib. Blood 2004;104(11):Abstract #1019.

101. Elliot VJ, Marin D, Horncastle D, et al. Total Number of CD34 + cells per ten high power fields in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response during the first year of treatment with imatinib. Blood 2004;104(11):Abstract #4664.

102. Lange T, Gunther C, Kohler T, et al. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003;101(6):2152-5.

103. McLean LA, Gathmann I, Capdeville R, et al. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clinical Cancer Research 2004;10(1 Pt 1):155-65.

104. Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 2003;17(12):2392-400.

105. Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002;16(9):1579-83.

106. Mueller MC, Paschka P, LaHaye T, et al. Molecular long-term surveillance of CML patients on imatinib therapy. follow-up of german patients treated within the IRIS trial. Blood 2004;104(11):Abstract #1003.

107. Press RD, Love Z, Tronnes AA, et al. BCR-ABL RNA levels at the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib-treated chronic myeloid leukemia patients. Blood 2004;104(11):Abstract #1098.

108. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2(2):117-25.

109. Frater JL, Tallman MS, Variakojis D, et al. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. American Journal of Clinical Pathology 2003;119(6):833-41.

110. Sneed TB, Kantarjian HM, Talpaz M, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100(1):116-21.

111. Kvasnicka HM, Thiele J, Staib P, et al. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 2004;103(9):3549-51.

112. Jabbour E, Kantarjian H, Jones D, et al. Long-term incidence and outcome of BCR-ABL mutations in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate P-loop mutations are not associated with worse outcome. Blood 2004;104(11):Abstract #1007.

113. Branford S, Rudzki Z, Grigg A, et al. The frequency of detection of BCR-ABL mutations in imatinib treated patients with chronic phase CML who attain a complete cytogenetic response (CCR) does not diminish with increasing duration of CCR but the associated loss of response is usually gradual. Blood 2004;104(11):Abstract #271.

114. Corm S, Nicollini F, Borie D, et al. Mutation status of imatinib mesylate-resistants CML patients and clinical outcomes: a French multicenter retrospective study for the fiLMC group. Blood 2004;104(11):Abstract #275.

115. Deininger MW, Willis S, Lange T, et al. Detection of imatinib-resistant BCR-ABL mutants in drug-naïve patients: correlation with disease phase and clonal evolution but not with response to treatment. Blood 2004;104(11):Abstract #273.

116. Hochhaus A. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Annals of Hematology 2004;83(Suppl 1):S65-66.

117. Shimoni A, Kroger N, Zander AR, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003;17(2):290-7.

118. Lange T, Bumm T, Mueller M, et al. Molecular remission to imatinib in patients with chronic myeloid leukaemia (CML) is less durable compared to patients after allografting. Blood 2004;104(11):Abstract #276.

119. Palandri F, Martinelli G, Amabile M, et al. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Blood 2004;104(11):Abstract #4655.

120. Pautas C, Nicolini F, Cony-Makhoul P, et al. Imatinib mesylate (IM), is an alternative to donor lymphocyte infusion (DLI) for chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation: a 3-year follow-up report, on the behalf of the Société Française de Greffe de Moëlle et de Thérapie Cellulaire (SFGM-TC) and the France Intergroupe de la Leucémie Myéloïde Chronique (Fi-LMC). Blood 2004;104(11):Abstract #1017.

121. Conneally E, Carroll P, Neat M, et al. Imatinib mesylate treatment of patients with chronic myeloid leukaemia relapsing following allogeneic stem cell transplantation. Blood 2004;104(11):Abstract #4659.

122. Laurence A, Marin D, Clark R, Shepherd P, Mackinnon S. Frequency of blast crisis after achieving complete cytogenetic remission in first chronic phase CML Patients Who received imatinib therapy within six months of diagnosis. Blood 2004;104(11):Abstract #1021.

123. George S, Horvath L, Molokie R, et al. Response to therapy with imatinib mesylate in patients with CML is poor in non-caucasian patients. Blood 2004;104(11):Abstract #2937.

124. Bassi S, Castagnetti F, Amabile M, et al. Imatinib in the treatment of CML Patients > 65 years old in late chronic phase: results of a Phase II Study of the GIMEMA CML Working Party. Blood 2004;104(11):Abstract #2935.

125. Martino B, Vincelli Y, Ronco F, et al. Efficacy and safety of imatinib treatment in elderly patients with chronic myeloid leukemia. Blood 2004;104(11):Abstract #4680.

126. Soverini S, Martinelli G, Amabile M, et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clinical Chemistry 2004;50(7):1205-13.

127. Issa S, Holdsworth D, Oei P, et al. The utility of peripheral Blood FISH in the quantitation of BCR/ABL in CML patients on imatinib mesylate: a comparison with bone marrow FISH and conventional cytogenetics. Blood 2004;104(11):Abstract #2942.

128. Thomazy VA, Kantarjian HM, Imam M, et al. Use of plasma RNA for real-time quantitative RT-PCR to monitor imatinib therapy in patients with chronic myeloid leukemia. Blood 2004;104(11):Abstract #1099.

129. Kagami Y, Katagiri T, Kaneta Y, et al. Validation study on the prediction of response to imatinib mesylate in chronic myeloid leukemia (CML) patients by genome-wide cDNA microarray analysis. Blood 2004;104(11):Abstract #2946.

130. Vallespí T, Borrego M, Colomé D, Jaen A, Rozman M, Massagué M. Quantitative polymerase chain reaction (qPCR) at diagnosis and follow-up of patients with chronic myeloid leukemia in treatment with imatinib. Blood 2004;104(11):Abstract #4688.

131. Paschka P, Branford S, Lorentz C, Hehlmann R, Hughes T, Hochhaus A. Comparison of "log reduction from median pretherapeutic value" vs ratio BCR-ABL/ABL to express the therapeutic response in CML patients. Blood 2004;104(11):Abstract #1013.

132. Albitar M, Cortes J, Giles F, et al. Molecular monitoring of chronic phase chronic myeloid leukemia patients treated with 800mg imatinib. Journal of Clinical Oncology 2005;23(16S):Abstract #6554.

133. Berger U, Hochhaus A, Reiter A, et al. Feasibility of imatinib combination therapies in a randomized trial for chronic myeloid leukemia: the German CML-Study IV—Pilot Phase. 2004;104(11):Abstract #24.

134. Hehlmann R, Hochhaus A, Berger U, Pfirrmann M, Hasford J. Concept and feasibility of the randomized comparison of imatinib with imatinib combination therapies for chronic myeloid leukemia: the German CML Study IV—Pilot Phase. Journal of Clinical Oncology 2005;23(16S):Abstract #6574.

135. Monroy RH, Vargas-Viveros P, Cervera E, et al. Imatinib alone (IA) vs. imatinib + Ara-C (IMAC): a randomized phase III clinical trial for the treatment of early phase (EP) chronic myeloid leukemia (CML) Ph+. Preliminary report of Mexican Cooperative Leukemia Group (GRUMELA). Blood 2004;104(11):Abstract #1015.

136. Fruehauf, Topaly, Buss EC, et al. A multicenter Phase I/II Trial of the combination of imatinib mesylate with mitoxantrone/etoposide and cytarabine in patients with CML in myeloid blast crisis: a trend to a longer survival in patients receiving more aggressive treatment schedules. Blood 2004;104(11):Abstract #2929.

137. Cornelissen JJVP, Verhoef GEG, Smit WM, et al. High rates of molecular response and low incidence of mutations in patients treated with newly diagnosed chronic myeloid leukemia (CML) treated with a dose-escalated combination of imatinib and cytarabin. Blood 2004;104(11):Abstract #19.

138. Rousselot P, Legros L, Guilhot J, et al. A Phase I/II dose escalating study of daunorubicin combined with imatinib mesylate and cytarabine as induction therapy for chronic myelogenous leukaemia in myeloid blast crisis. Preliminary results of the AFR01 trial. Blood 2004;104(11):Abstract #1002.

139. Ceglarek BB, Konopka LJ, Sikorska A, et al. Gleevec therapy in advanced phases of the CML-Polish study report. Blood 2004;104(11):Abstract #4701.

140. Cortes J, Giles F, Salvado A, et al. High dose (HD) imatinib in patients with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): preliminary results of a multicenter community based trial. Journal of Clinical Oncology 2005;23(16S):Abstract #6518.

141. Sacchi S, Kantarjian HK, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase. Cancer 1999;86(12):2632-41.

142. Gratwohl A, Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation May 1996;17 Suppl 3:S7-9.

143. Bacik J, Mazumdar M, Murphy BA, et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res Feb 2004;13(1):137-54.

144. Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105(6):2281-6.

145. White DL, Saunders VA, Branford S, Lyons B, Hughes TP. The combination of intrinsic sensitivity to imatinib and sokal prognostic score is strongly predictive of molecular response in newly diagnosed CML patients treated with imatinib. Blood 2004;104(11):Abstract #1008.

146. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science Aug 3 2001;293(5531):876-80.

147. Johnson JR, Bross P, Cohen M, et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clinical Cancer Research 2003;9(6):1972-9.

148. Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clinical Cancer Research Jan 1 2005;11(1):12-9.

149. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood Mar 1 2002;99(5):1527-35.

150. Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. Journal of Clinical Oncology May 1992;10(5):772-8.

151. Personal communication with Kelly Moore. Novartis 5-19-2005.

152. McLean LA, Gathmann I, Capdeville R, Polymeropoulos MH, Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clinical Cancer Research Jan 1 2004;10(1 Pt 1):155-65.

153. Savage DG, Antman KH. Imatinib mesylate?a new oral targeted therapy. New England Journal of Medicine 2002;346(9):683-93.

154. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood Nov 1 2004;104(9):2926-32.

155. Lange T, Bumm T, Mueller M, et al. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia 2004;19:1262-9.

156. Crossman LC, Mori M, Hsieh YC, et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 2005;90:459-64.

157. Kaneta Y, Kagami Y, Katagiri T, et al. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Japanese Journal of Cancer Research 2002;93:849-56.

158. Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood 2005;106(3):1133-4.

Return to Contents
Proceed to Next Section

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care